Brandon L. Prendes

Brandon L. Prendes

Auto-generated profile, based on publicly available information

Brandon L. Prendes

Head & Neck Institute, Cleveland Clinic, Cleveland, OH, USA

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2017 in American Journal of Otolaryngology
Verified
Journal Article
Closed access
STSamuel J. Trosman
Samuel J. Trosman
RBRohith Bhargavan
Rohith Bhargavan
BPBrandon L. Prendes
Brandon L. Prendes
BBBrian B. Burkey
Brian B. Burkey
JSJoseph Scharpf
Joseph Scharpf

30 June 2021 in Current Oncology
Verified
Journal Article
Open access
PDF file
ABArslan Babar
Arslan Babar
NWNeil M. Woody
Neil M. Woody
AGAhmed I Ghanem
Ahmed I Ghanem
JTJillian Tsai
Jillian Tsai
NDNeal E. Dunlap
Neal E. Dunlap
JGJessica Geiger
Jessica Geiger
Adjuvant chemoradiation (CRT), with high-dose cisplatin remains standard treatment for oral cavity squamous cell carcinoma (OCSCC) with high-risk pathologic features. We evaluated outcomes associated with different cisplatin dosing and schedules, concurrent with radiation (RT), and the effect of cumulative dosing of cisplatin. An IRB-approved collaborative database of patients (pts) with primary OCSCC (Stage I–IVB AJCC 7th edition) treated with primary surgical resection between January 2005 and January 2015, with or without adjuvant therapy, was established from six academic institutions. Patients were categorized by cisplatin dose and schedule, and resultant groups compared for demographic data, pathologic features, and outcomes by statistical analysis to determine disease free survival (DFS) and freedom from metastatic disease (DM). From a total sample size of 1282 pts, 196 pts were identified with high-risk features who were treated with adjuvant CRT. Administration schedule of cisplatin was not significantly associated with DFS. On multivariate (MVA), DFS was significantly better in patients without perineural invasion (PNI) and in those receiving ≥200 mg/m2 cisplatin dose (p < 0.001 and 0.007). Median DFS, by cisplatin dose, was 10.5 (<200 mg/m2) vs. 20.8 months (≥200 mg/m2). Our analysis demonstrated cumulative cisplatin dose ≥200 mg/m2 was associated with improved DFS in high-risk resected OCSCC pts.

18 August 2023 in Endocrine Practice
Verified
Journal Article
Closed access
SWShannon Wu
Shannon Wu
EMEric Lamarre MD
Eric Lamarre MD
JSJoseph Scharpf
Joseph Scharpf
BPBrandon Prendes
Brandon Prendes
JKJamie A. Ku
Jamie A. Ku
JGJessica Geiger
Jessica Geiger

16 July 2024 in Oral Oncology
Verified
Journal Article
Open access
KCKevin J. Contrera
Kevin J. Contrera
CMChengetai R. Mahomva
Chengetai R. Mahomva
BSBhavya K. Sharma
Bhavya K. Sharma
WWWei Wei
Wei Wei
BBBrian B. Burkey
Brian B. Burkey
BPBrandon L. Prendes
Brandon L. Prendes
Advancements in immunotherapy for recurrent head and neck cancer have necessitated a better understanding of salvage surgical outcomes. This study aimed to determine patterns of failure following salvage head and neck surgery. A retrospective cohort study was conducted of 280 patients who underwent salvage surgery for recurrent mucosal squamous cell carcinoma from 1997 to 2018. Cumulative incidence was calculated using the nonparametric Aalen-Johansen estimator. Time to recurrence (TTR) and overall survival (OS) were estimated using the Kaplan-Meier method and multivariable Cox proportional hazard models were used to evaluate associated factors. The 2 and 5-year cumulative incidence rates of second recurrence were 48.3 % (95 % CI 42.4-54.3) and 54.9 % (95 % CI 48.9-60.8), respectively. At 5 years, second locoregional recurrence was twice as common as distant recurrence (41.5 % [95 % CI 35.6-47.4] vs. 21.7 % [95 % CI 16.8-26.6]). The median TTR was 21.1 months (95 % CI 4.4-34.8), which varied by site (38.2 larynx/hypopharynx, 13.9 oral cavity, 8.3 sinonasal, and 7.8 oropharynx, P=.0001). The median OS was 32.1 months (95 % CI 24.1-47.6) and was worse for patients who were Black (hazard ratio [HR] 2.15, 95 % CI 1.19-3.9), current smokers (HR 2.73, 95 % CI 1.53-4.88), former smokers (HR 2.00, 95 % CI 1.19-3.35), ≥ 60 years of age (HR 1.41, 95 % CI 1.01-1.97), or received multimodal primary therapy (HR 1.98, 95 % CI 1.26-3.13). Rates of recurrence and mortality after salvage surgery were poor but worse for patients who were Black, older, smoked, had initial multimodal therapy, or had sinonasal or oropharyngeal cancers.

4 July 2024 in Current Opinion in Otolaryngology & Head and Neck Surgery
Verified
Journal Article
Closed access
LSLindsey Shehee
Lindsey Shehee
DBDanielle Bottalico
Danielle Bottalico
BPBrandon Prendes
Brandon Prendes
Purpose of review: Surgery, radiation, and chemotherapy are often utilized in the treatment of head and neck cancer. These treatments can cause extensive scarring within the neck and can limit the viability of recipient vessels for further microvascular reconstruction. Patients with vessel-depleted necks provide a significant challenge for microvascular surgeons and are a topic of much discussion in the field. Recent findings: While reconstruction in the vessel-depleted neck is an active area of interest, the patient population is rare. Therefore, single institution series with small numbers comprise the majority of published literature. Recent publications describe techniques for identifying adequate recipient vessel options outside of the field of treatment with excellent free flap outcomes. Further, recent summary articles describe techniques for addressing issues with pedicle length that can arise when using vessels that are far from the defect to be reconstructed. Summary: When viable vessel options are available within the treatment field, these recipient vessels can be used with good reliability and free flap success. If in-field recipient vessels are not available, minimal access incisions can be used to identify superficial temporal, angular, contralateral facial, or transverse cervical vessels. Further away from the treatment field, internal mammary vessels can be harvested through open or robotic approaches. If the use of these distant vessels creates issues with pedicle length, interposition vein grafts, arteriovenous (AV) loops, or flow-through flaps can be used to augment vessel length.

24 September 2024 in Oral Oncology
Verified
Journal Article
Closed access
KCKevin J. Contrera
Kevin J. Contrera
BPBrandon L. Prendes
Brandon L. Prendes